Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCT Combined With BCMA-CAR-T for Ultra-High Risk Multiple Myeloma
NCT07109323Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of BCMA-CAR-T in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Mar 2025; status: recruiting.
02
Drugs
BCMA-CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07109323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07109323.